Dr. Karakousis and his team are using a systems biology-based approach to understand the immunological basis of latent tuberculosis infection and reactivation disease.

He is interested in identifying novel biomarkers for predicting the risk of reactivation and assessing the adequacy of tuberculosis treatment.